At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 40 enrolled
Drug / intervention
LY3493269 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3493269 in Healthy Participants
In Brief
A Phase 1 clinical trial evaluating LY3493269 and Placebo for Healthy. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The main purpose of this study in healthy participants is to learn more about the safety of LY3493269 and any side effects that might be associated with it. Blood tests will be performed to check how much LY3493269 gets into the bloodstream and how long it takes the body to eliminate it. For each participant, the study will last about 10 weeks and may include 12 visits, including five nights in a row in the clinical research center.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSingapore
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartSep 2020
Primary CompletionDec 2020
TodayJul 2026
First PostedAug 4, 2020
Enrollment StartSep 3, 2020
Primary CompletionDec 28, 2020
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.9 years ago
Interventions
LY3493269drug
Administered orally.
Placebodrug
Administered orally.